. "RIV/00216224:14110/09:00036666" . . "Aktivita cytochromu P4502D6 p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B paroxetinem ve srovn\u00E1n\u00ED se zdrav\u00FDmi dobrovoln\u00EDky"@cs . "Aktivita cytochromu P4502D6 p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B paroxetinem ve srovn\u00E1n\u00ED se zdrav\u00FDmi dobrovoln\u00EDky"@cs . . "CYP2D6; phenotype; paroxetine"@en . "2"^^ . "CZ - \u010Cesk\u00E1 republika" . "CYP2D6 activity in patients long-term treated with paroxetine and comparison with healthy volunteers"@en . "Aktivita cytochromu P4502D6 p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B paroxetinem ve srovn\u00E1n\u00ED se zdrav\u00FDmi dobrovoln\u00EDky" . . . "\u017Dourkov\u00E1, Alexandra" . . "1211-7579" . "CYP2D6 activity in patients long-term treated with paroxetine and comparison with healthy volunteers"@en . "4"^^ . "Z(MSM0021622404)" . "[1CB80E632270]" . . "302277" . "Slana\u0159, Old\u0159ich" . "Totally 56 patients with depressive or anxiety disorder treated with paroxetine were enrolled into the study. Age-, and sex-matched control group was created from 56 volunteers. The aim of our study war to evaluate into which extent is CYP2D6 phenotype affected by paroxetine treatment in relation to CYP2D6 genotype. Paroxetine treatment leads to a hyghly significant reduction of CYP2D6 activity in subject genotyped as wild-type EMs."@en . . . . "Aktivita cytochromu P4502D6 p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B paroxetinem ve srovn\u00E1n\u00ED se zdrav\u00FDmi dobrovoln\u00EDky" . "RIV/00216224:14110/09:00036666!RIV10-MSM-14110___" . . . "Psychiatrie \u010Dasopis pro modern\u00ED psychiatrii" . "2"^^ . "Do komparativn\u00ED studie bylo za\u0159azeno celkem 56 pacietn\u016F s depresivn\u00ED nebo anxi\u00F3zn\u00ED poruchou l\u00E9\u010Den\u00FDch paroxetinem. Kontroln\u00ED soubor sest\u00E1val z 56 v\u011Bkem a pohlav\u00EDm odpov\u00EDdaj\u00EDc\u00EDch dobrovoln\u00EDk\u016F. C\u00EDlem studie bylo stanovit, jak ovliv\u0148uje l\u00E9\u010Dba paroxetinem fenotyp CYP2D6 ve vztahu ke genotypu CYP2D6. L\u00E9\u010Dba paroxetinem vedla k v\u00FDznamn\u00E9mu sn\u00ED\u017Een\u00ED metabolick\u00E9 aktivity CYP2D6 ve skupin\u011B pacient\u016F s genetickou v\u00FDbavou odpov\u00EDdaj\u00EDc\u00ED extenzivn\u00EDm metaboliz\u00E1tor\u016Fm."@cs . "Ju\u0159ica, Jan" . "suppl. 2" . . . "13" . . . "Ve\u010De\u0159ov\u00E1, Monika" . "14110" . "Do komparativn\u00ED studie bylo za\u0159azeno celkem 56 pacietn\u016F s depresivn\u00ED nebo anxi\u00F3zn\u00ED poruchou l\u00E9\u010Den\u00FDch paroxetinem. Kontroln\u00ED soubor sest\u00E1val z 56 v\u011Bkem a pohlav\u00EDm odpov\u00EDdaj\u00EDc\u00EDch dobrovoln\u00EDk\u016F. C\u00EDlem studie bylo stanovit, jak ovliv\u0148uje l\u00E9\u010Dba paroxetinem fenotyp CYP2D6 ve vztahu ke genotypu CYP2D6. L\u00E9\u010Dba paroxetinem vedla k v\u00FDznamn\u00E9mu sn\u00ED\u017Een\u00ED metabolick\u00E9 aktivity CYP2D6 ve skupin\u011B pacient\u016F s genetickou v\u00FDbavou odpov\u00EDdaj\u00EDc\u00ED extenzivn\u00EDm metaboliz\u00E1tor\u016Fm." .